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Abstract 
Background: In phenylketonuria (PKU), modified casein glycomacropeptide supplements (CGMP-AA) are used as 
an alternative to the traditional phenylalanine (Phe)-free L-amino acid supplements (L-AA). However, studies focusing 
on the long-term nutritional status of CGMP-AA are lacking. This retrospective study evaluated the long-term impact 
of CGMP-AA over a mean of 29 months in 11 patients with a mean age at CGMP-AA onset of 28 years (range 15–43) 
[8 females; 2 hyperphenylalaninaemia (HPA), 3 mild PKU, 3 classical PKU and 3 late-diagnosed]. Outcome measures 
included metabolic control, anthropometry, body composition and biochemical parameters.
Results: CGMP-AA, providing 66% of protein equivalent intake from protein substitute, was associated with no signif-
icant change in blood Phe with CGMP-AA compared with baseline (562 ± 289 µmol/L vs 628 ± 317 µmol/L; p = 0.065). 
In contrast, blood tyrosine significantly increased on CGMP-AA (52.0 ± 19.2 μmol/L vs 61.4 ± 23.8 μmol/L; p = 0.027).
Conclusions: Biochemical nutritional markers remained unchanged which is an encouraging finding in adults with 
PKU, many of whom are unable to maintain full adherence with nutritionally fortified protein substitutes. Longitudinal, 
prospective studies with larger sample sizes are necessary to fully understand the metabolic impact of using CGMP-
AA in PKU.
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Introduction
Phenylketonuria (PKU, OMIM # 261,600) is an inborn 
error of phenylalanine (Phe) metabolism caused by defi-
ciency of phenylalanine hydroxylase [1]. PKU is success-
fully managed by a Phe-restricted diet supplemented 
with Phe-free L-amino acid supplements (L-AA) [2]. In 
recent years, casein glycomacropeptide (CGMP) has 
been prescribed as an alternative protein substitute in 
PKU. CGMP is a whey-based bioactive peptide derived 
from the cheese-making process and it is potentially val-
uable for human health, particularly in PKU [3].
Commercial formulations of CGMP are supplemented 
with rate-limiting amino acids (CGMP-AA) as methio-
nine, leucine (Leu), lysine, arginine, tyrosine (Tyr) and 
tryptophan [4] to improve their suitability in patients 
with PKU. However, a disadvantage of CGMP-AA com-
pared with L-AA is that it contains some residual Phe. 
Most formulations contain around 36  mg per 20  g pro-
tein equivalent [5].
In PKU, adherence to protein substitute is an ongoing 
challenge [6]. Recently, an Italian research group, using a 
survey to characterize the dietary habits of adult patients, 
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showed that the intrinsic features of L-AA (e.g., palatabil-
ity) are a cause of poor adherence [7]. In contrast, studies 
addressing the overall patient acceptability of CGMP-AA 
compared with their usual L-AA indicate good accept-
ance [8]. A sensory study suggested that CGMP-AA 
may enhance patients’ adherence and therefore improve 
health status [9].
CGMP-AA has many functional and physiological 
properties. It acts as a prebiotic, increases the production 
of short-chain fatty acids (SCFA), has anti-inflammatory 
properties and exerts beneficial effects on bone, creating 
an attractive peptide for patients with PKU [10].
Over time, PKU treatment has been refined and opti-
mized in order to avoid the negative effects on overall 
health status of low and inconsistent intake of a macro- 
and micronutrient- supplemented L-AA [11]. However, 
studies addressing the long-term effect of CGMP-AA on 
nutritional status are lacking.
The purpose of the present study is to expand on previ-
ous data published by Pinto et al. [12] by increasing the 
duration of follow-up of a group of 11 patients with PKU 
taking CGMP-AA. In Pinto’s study, blood Phe remained 
unchanged whereas blood Tyr increased whilst taking 
57% of CGMP-AA as protein substitute in combination 
with L-AA [12]. A meta-analysis performed by our group 
also demonstrated no significant differences between 
CGMP-AA and L-AA for blood Phe and Tyr control in 
adults with PKU [8]. However, the use of CGMP-AA in 
children does adversely affect blood Phe control [13–15] 
and so there is concern about using CGMP-AA as the 
sole source of protein substitute in children and preg-
nancy. A first case report from our group revealed no 
deterioration of metabolic control during pregnancy 
when combined with L-AA [16]. A recent longitudinal, 
parallel, controlled study over 12 months assessing a for-
mulation of CGMP-AA compared with L-AA on blood 
Phe, Tyr, Phe/Tyr ratio, biochemical nutritional status 
and growth in children with PKU identified no differ-
ences for the majority of the parameters that remained 
within the reference ranges, although CGMP-AA only 
provided 75% of the total protein substitute source. A 
significant increase in selenium and decrease in ferritin 
were observed [5].
The main aim of this study was to evaluate the longi-
tudinal impact of the use of CGMP-AA in patients with 
PKU.
Materials and methods
Study design and participants selection
We conducted a retrospective longitudinal study of 
patients being treated for PKU and exclusively followed-
up at Centro de Genética Médica, Centro Hospitalar 
Universitário do Porto. Patients were given CGMP-AA as 
their primary nitrogen source if they had difficulties with 
taking L-AA or if CGMP-AA was considered a suitable 
alternative.
The inclusion criteria were diagnosis of PKU, absence 
of co-existent conditions and taking CGMP-AA as part 
of their protein substitute prescription. Exclusion criteria 
were the use of sapropterin, use of large neutral amino 
acids, pregnancy, lack of biochemical markers or body 
composition analysis.
All patients followed a low-Phe diet, avoiding high 
protein foods, and supplemented with L-AA and special 
low protein foods. Phe intake was controlled using a Phe 
exchange system (1 exchange = 20 mg of Phe).
The present study included data on 11 patients from 
a previous study reported by Pinto et  al. [12] but an 
extended follow-up period of 2.9  years if patients 
remained on CGMP-AA.
Data was collected between May 2013 and Decem-
ber 2018, whereas the previous study by Pinto et  al. 
[12] retrieved data until February 2016. The first annual 
nutritional status evaluation (ANSE) was performed 
when taking L-AA and the last ANSE with the addi-
tion of CGMP-AA. The baseline assessment was con-
ducted for a mean of 6  months before CGMP-AA 
commencement when patients were taking L-AA only 
as their primary nitrogen source. The last assessment 
was carried out when CGMP-AA had been given for a 
mean of 29  months. CGMP-AA either fully or partially 
replaced L-AA; CGMP-AA contribution to the total pro-
tein substitute intake was: 100%, n = 4, 50% to < 100%, 
n = 4, < 50%, n = 3. This was according to patient’s protein 
substitute preference or by the nutritionist’s prescrip-
tion after assessing metabolic control, nutritional status, 
nutritional intake, anthropometry and body composition.
The PKU classification was based on the Portu-
guese guidelines as follows: hyperphenylalaninae-
mia (HPA) [blood Phe < 360  µmol/L (6  mg/dL)]; mild 
PKU [blood Phe ≥ 360  µmol/L and ≤ 1200  µmol/L 
(≥ 6  mg/dL and ≤ 20  mg/dL)] and classical PKU [blood 
Phe > 1200 µmol/L (> 20 mg/dL)] [17].
Blood Phe and Tyr control was also evaluated over 
2-time intervals as follows: i) from May 2013 until 
CGMP-AA introduction (13 ± 5  months) and ii) from 
CGMP-AA introduction until the last ANSE taking 
CGMP-AA (29 ± 16  months). The median number of 
blood Phe measurements while patients were taking 
L-AA was 11 (7–16) and with CGMP-AA was 40 (21–71).
The study design is presented in Fig. 1.
Data collection and outcomes measured
The following parameters were collected from patients’ 
records by trained research nutritionists (M.J.P. and A.P.):
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Anthropometry
Height (cm) was measured with light clothes, using a 
stadiometer (SECA GmbH & CO., Hamburg, Germany) 
(measured to the nearest millimetre) and weight (kg) was 
assessed with a mechanical weighing scale (SECA GmbH 
& CO., Hamburg, Germany) (measured to the nearest 
100  g). Waist circumference (WC) (cm) was measured 
in the standing position, midway between the lower rib 
margin and the iliac crest, at the end of a normal exhala-
tion, to the nearest millimetre and using a non-extensive 
metric tape. Anthropometric measures were performed 
by trained nutritionists (M.F.A. and J.C.R.).
Body composition analysis
Body composition was performed in the fasted state 
using a single-frequency (50  Hz) bioelectrical imped-
ance analyzer, Akern, Quantum/S (RJL systems, Florence, 
Italy) according to described standards and measurement 
conditions. Total fat mass, percentage of body fat mass, 
percentage of lean mass and phase angle were assessed 
in the programme BodyGram™ version 1.3 (Akern Biore-
search, Florence, Italy) which uses validated prediction 
equations [18]. The measures were carried out by trained 
nutritionists (M.F.A. and J.C.R.).
Nutritional intake
Total protein intake, natural protein intake (g/kg/day), 
protein equivalent from the protein substitute (g/kg/day 
and g/day), Phe intake (mg/day) from both natural foods 
and CGMP-AA, Tyr (g/day) and Leu (g/day) intake from 
the protein substitutes were calculated using a 24-h food 
recall. Dietary assessments were performed by M.F.A. 
and J.C.R..
Biochemical markers
Blood samples for biochemical analysis were taken after 
an overnight fast. Uric acid, glucose, creatinine, urea, 
glycated haemoglobin (HbA1c), lipid panel [total cho-
lesterol, triglycerides, high-density lipoprotein (HDL)-
cholesterol, low-density lipoprotein (LDL)-cholesterol, 
very low-density lipoproteins (VLDL)-cholesterol, apoli-
poprotein A1, apolipoprotein B], iron, transferrin, fer-
ritin, albumin, homocysteine, prealbumin, C-reactive 
protein, insulin, calcium, phosphorus, selenium, zinc, 
vitamin B12, vitamin D and folic acid were determined. 
Blood urea nitrogen (BUN) was calculated from urea and 
homeostatic model of insulin resistance (HOMA-IR) was 
calculated as follows: HOMA-IR = fasting plasma glucose 
(mg/dL) × fasting serum insulin (μU/mL)/405 [19].
Blood pressure
A Critikon Dinamap™ vital signs monitor 8100 was used 
to measure resting systolic and diastolic blood pressure 
and heart rate with individuals seated for at least 5 min, 
according to standard techniques.
Fig. 1 Study design. ANSE, annual nutritional status evaluation; CGMP-AA, casein glycomacropeptide supplements; HPA, hyperphenylalaninaemia; 
L-AA, phenylalanine-free L-amino acid supplements; PKU, phenylketonuria
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Metabolic control
Blood Phe and Tyr were measured by fasting blood spots 
and analysed by tandem mass spectrometry. Patients or 
Caregivers were trained to perform routine blood spots. 
Good metabolic control was defined as median blood Phe 
level within 120–360 µmol/L (2–6 mg/dL) ≤ 12 years or 
120–480 µmol/L (2–8 mg/dL) > 12 years of age, according 
to the Portuguese criteria [20]. The percentage of median 
blood Phe within the target range was also calculated.
Overweight/obesity
Body mass index (BMI) was calculated as the ratio of 
weight (kg) and height  (m2) and classified according to 
the World Health Organisation (WHO) criteria. Over-
weight and obesity were defined when BMI was between 
25.0 and 29.9  kg/m2 or was ≥ 30.0  kg/m2, respectively 
[21]. The Anthro Plus® programme version 1.0.4 was 
used to calculate the BMI z-scores for individuals under 
19  years. Overweight and obesity were identified when 
the BMI z-score was between 1 and 2 standard deviations 
(S.D.) or above 2 S.D., respectively [22].
Statistical analysis
All statistical analyses were performed with SPSS® ver-
sion 26.0 for Mac (IBM Company, Chicago, IL, USA). 
Normal distribution was checked using Shapiro–Wilk 
test. Categorical variables are expressed as percent-
age and continuous variables as mean ± S.D. or median 
(P25–P75) where appropriate. Paired t-test and Wilcoxon 
signed ranks test   were used to analyse the differences 
when normal distribution or non-normal was found, 
respectively. The McNemar test was used to determine if 
there are differences on a dichotomous dependent vari-
able between 2 related groups. Significance was set at the 
level of p value less than 0.05.
Results
Characteristics of patients with PKU
Table 1 summarizes the main features of the 11 patients 
included in this study (8 females and 3 males). The mean 
age at CGMP-AA onset was 28 years (range 15 to 43) (1 
patient was < 18 years: 15 years, n = 1). In this cohort of 
patients, 2 of 11 had HPA, 3 mild PKU, 3 classical PKU 
and 3 were late-diagnosed. The mean length of time on 
CGMP-AA was 29 months (range 6 to 48).
Nutritional intake
Table 2 shows the type of protein substitute used in each 
assessment. The L-AA formulations prescribed were 
mainly powders and liquids. Subjects usually took more 
than one type of L-AA. The majority of patients (n = 9; 
82%) were treated with the same formulation of CGMP-
AA, Glytactin BetterMilk® (Cambrooke, USA). Five of 11 
patients took CGMP-AA for  less than 2  years. The rea-
sons why patients stopped taking CGMP-AA were poor 
dietary adherence (n = 1), temporary loss of follow-up 
(n = 1), sapropterin therapy (n = 2) and pregnancy (n = 1).
At the last ANSE, CGMP-AA contributed a mean of 
66 ± 31% (range 23 to 100) to the total protein substi-
tute intake. The mean Phe provided by CGMP-AA was 
44 mg/day (range 23 to 73).
Table 1 Characteristics of patients with PKU included in the study
ANSE, annual nutritional status evaluation; CGMP-AA, casein glycomacropeptide supplements; HPA, hyperphenylalaninaemia; ID, identification; L-AA, phenylalanine-
free L-amino acid supplements; N/A, not available; NBS, newborn screening; Phe, phenylalanine; PKU, phenylketonuria






















1 240 L249F A300S HPA 17 18 6 100
2 N/A I65T R270K Late-diagnosed 42 43 47 60
3 720 I65T I65T Mild PKU 26 27 27 23
4 N/A IVS10-11G>A V388M Late-diagnosed 40 41 42 60
5 1260 IVS11+5G>A 165T Classical PKU 25 26 38 100
6 N/A R158Q R252W Late-diagnosed 37 38 7 27
7 780 I65T IVS10-11G>A Mild PKU 18 20 20 28
8 2580 IVS10-11G>A IVS10-11G>A Classical PKU 24 27 48 100
9 1260 P281L P281L Classical PKU 29 31 16 52
10 420 R261Q E390G HPA 13 15 44 100
11 840 IVS10-11G>A R270K Mild PKU 21 23 21 75
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Table 3 describes metabolic control, nutritional intake, 
anthropometry and body composition of the partici-
pants when taking L-AA compared with CGMP-AA. 
The total amount of protein equivalent from protein 
substitute remained unchanged [(0.86 ± 0.24  g/kg/day 
vs 0.74 ± 0.23  g/kg/day; p = 0.126) and (50.8 ± 16.3  g/
day vs 44.6 ± 12.8  g/day; p = 0.118)]. The intake of Tyr 
was not affected with CGMP-AA (5.18 ± 1.77  g/day 
vs 4.22 ± 1.59  g/day; p = 0.145). Natural protein and 
Phe ingestion stratified according to the percentage 
of CGMP-AA intake of the 11 patients with PKU tak-
ing L-AA vs CGMP-AA is shown in Additional file  1: 
Table S1.
Anthropometry and body composition analysis
Table 3 describes parameters of anthropometry and body 
composition of all patients taking L-AA compared with 
CGMP-AA. Patients on CGMP-AA had a tendency for 
increased body weight (60.4 ± 15.2  kg vs 63.4 ± 13.2  kg; 
p = 0.064) and total body fat (17.3 ± 13.5  kg vs 
19.5 ± 12.3  kg; p = 0.056) when compared to baseline 
with L-AA. However, the overall percentage of over-
weight and obesity in patients taking L-AA (46%) vs 
CGMP-AA (46%) remained unchanged (p = 1.000).
Biochemical markers and blood pressure
There were no differences in the biochemical and blood 
pressure data (Table 4).
Metabolic control
Table 3 describes metabolic control. Blood Phe concen-
trations were similar between baseline and CGMP-AA 
(562 ± 289  µmol/L vs 628 ± 317  µmol/L; p = 0.065). The 
percentage of patients with median blood Phe within tar-
get range did not change (36% vs 36%, p = 1.000). In the 
subgroup of patients with 100% CGMP-AA (n = 4), half 
of the patients had good metabolic control and the other 
half did not.
Blood Tyr significantly increased with CGMP-AA 
(52.0 ± 19.2  μmol/L vs 61.4 ± 23.8  μmol/L; p = 0.027). 
Metabolic control stratified according to the percentage 
of CGMP-AA intake of the 11 patients with PKU tak-
ing L-AA vs CGMP-AA is shown in Additional file  1: 
Table S2.
Figures 2 and 3 show the metabolic control of Phe and 
Tyr control between baseline and the last assessment.
Discussion
This PKU study was the continuation of the work per-
formed by Pinto et  al. [12] and it is the only report 
describing the nutritional status of adults taking CGMP-
AA for a mean period of 2.4 years. CGMP-AA provided 
a mean 66% of the total protein substitute source (only 
4 patients took 100% of protein substitute requirement 
as CGMP-AA), which was a small increase compared 
with the 57% from our previous report [12]. Only 6 of 11 
patients took CGMP-AA for over 2 years.
There were no changes in blood Phe levels in this older 
cohort of patients with PKU, which is in line with the 
previous findings with CGMP-AA studies [12], although 
patients ≥ 12 years of age maintained higher upper target 
blood Phe levels than children. In addition, half of our 
cohort had mild forms of PKU with a high Phe tolerance 
and so any extra Phe provided by CGMP-AA might not 
have affected the blood Phe levels [23]. Also, CGMP-AA 
only contributed partially to the total protein substitute 
Table 2 Type of protein substitute used in each assessment
CGMP-AA, casein glycomacropeptide supplements; L-AA, phenylalanine-free L-amino acid supplements; PKU, phenylketonuria; RTD, ready to drink; L-AAt, type of 
protein substitute when taking L-AA; CGMP-AAt, type of protein substitute when taking CGMP-AA
Forms L-AAt CGMP-AAt
L-AA CGMP-AA





PhenylAde® (Taranis) (n = 2)
PKU 2 Secunda® (Nutricia) (n = 1)
PKU Anamix Junior® (Nutricia) (n = 1)
Phlexy 10 Drink Mix® (Nutricia) (n = 1)
Liquids PKU Cooler 10, 15 and 20® (Vitaflo) (n = 9)
XPhe Jump 10® (MetaX) (n = 1)
PKU Cooler 10, 15 and 20® (Vitaflo) 
(n = 5)










Bars PhenylAde Amino Acid Bar® (Taranis) (n = 1)
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intake [24]. Finally, this was a small cohort of patients 
and the study was not powered to find a statistical change 
based on such small numbers.
Interestingly, an increase in blood Tyr was observed 
despite no difference in intake. The putative explanation 
for this finding can be related to better adherence with 
the protein substitute. Although L-AA contains higher 
amounts of Tyr compared to CGMP-AA, its bioavailabil-
ity may be compromised due to lower solubility proper-
ties [25]. There is a suggestion that gut microbiota may 
contribute to less bioavailability of Tyr from L-AA [26], 
leading to lower blood Tyr levels. Considering diet is one 
of the main factors determining the gut microbiota which 
has been shown to interact with host metabolism [27], 
it is important to explore how the synthetic diet in PKU 
influences the configuration of the microbial community 
in the gut. It is possible that CGMP-AA also influences 
its composition. Theoretically, a diet poor or rich in cer-
tain nutrients may trigger an intestinal dysbiosis with 
systemic repercussions, such as obesity, diabetes, cancer, 
among others [28]. Studies sought to identify the effects 
of PKU diet on the microbiota are scarce, especially with 
CGMP-AA [26, 29].
In contrast to the Pinto et al. [12] study, HbA1c did not 
change in patients taking CGMP-AA. Even though, L-AA 
seems to lower glucose levels when compared to intact 
protein [30], further studies are needed to understand 
how chronic administration of protein substitute may 
influence glucose metabolism.
Biochemical biomarkers remained unchanged. BUN, 
a serum byproduct of protein metabolism that can be 
affected by dietary protein intake was similar to baseline 
on L-AA. This was comparable to previous reports [13, 
31, 32] but also contradicts studies that found signifi-
cantly lower levels with CGMP-AA [33, 34].
There was no impact on body composition and there 
was a trend for increased weight. The specific brand of 
CGMP-AA used by the majority of patients was higher 
Table 3 Overall metabolic control, nutritional intake, anthropometry and body composition of the 11 patients with PKU 
taking L-AA versus CGMP-AA
BMI, body mass index; CHO, carbohydrate; CGMP-AA, casein glycomacropeptide supplements; L-AA, phenylalanine-free L-amino acid supplements; Leu, leucine; 
Phe, phenylalanine; PKU, phenylketonuria; Tyr, tyrosine;  TL-AA, annual nutritional status evaluation under L-AA;  TCGMP-AA, last annual nutritional status evaluation 
under CGMP-AA; WC, waist circumference. Data are presented as mean ± S.D. (n) or median (P25–P75) (n). Paired t-test and Wilcoxon test were performed to identify 
differences when normal distribution or non-normal was found, respectively. Significance was set at the level of p value less than 0.05 and highlighted in bold. * Mean 
BMI was only calculated for adults
Profile n TL-AA TCGMP-AA p value
Metabolic control
 Median blood Phe (µmol/L) 11 562 ± 289 628 ± 317 0.065
 Median blood Tyr (μmol/L) 11 52.0 ± 19.2 61.4 ± 23.8 0.027
 Median blood Phe/Tyr ratio 11 15.1 ± 10.8 12.0 ± 8.8 0.379
Nutritional intake
 Natural protein intake (g/kg/day) 11 0.41 (0.26–0.62) 0.34 (0.21–0.69) 0.657
 Protein substitute (g/kg/day) 11 0.86 ± 0.24 0.74 ± 0.23 0.126
 Protein substitute (g/day) 11 50.8 ± 16.3 44.6 ± 12.8 0.118
 Phe intake (mg/day) 11 885 (751–1787) 978 (658–1370) 0.721
 Phe intake from protein substitute (mg/day) 11 0 43.5 ± 17.4 –
 Tyr intake from protein substitute (g/day) 11 5.18 ± 1.77 4.22 ± 1.59 0.145
 Leu intake from protein substitute (g/day) 11 5.85 (4.49–7.61) 7.97 (6.85–8.78) 0.075
 Protein (%) 11 13.8 ± 2.25 13.6 ± 2.25 0.696
 Fat (%) 11 26.9 ± 5.0 27.6 ± 4.2 0.503
 CHO (%) 11 57.0 (52.1–60.1) 58.5 (55.8–60.2) 0.248
 Energy (kcal/day) 11 2277 ± 551 2238 ± 491 0.793
Anthropometry and body composition
 Weight (kg) 11 60.4 ± 15.2 63.4 ± 13.2 0.064
 Height (cm) 11 158.6 ± 6.4 160.6 ± 9.8 0.341
 WC (cm) 11 85.1 ± 15.2 86.2 ± 14.3 0.536
 BMI (kg/m2) * 9 24.3 ± 6.2 25.1 ± 5.6 0.095
 Body fat (kg) 9 17.3 ± 13.5 19.5 ± 12.3 0.056
 Body fat (%) 9 25.5 ± 16.1 28.9 ± 13.4 0.126
 Lean mass (%) 9 74.5 ± 16.1 71.1 ± 13.4 0.126
 Phase angle (°) 9 6.8 ± 0.7 6.8 ± 0.6 0.880
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in energy compared with the L-AA given. There is sug-
gestion that CGMP-AA increases satiety and a similar 
energy intake between baseline and the last assessment 
was observed [35]. However, any change in weight 
should be interpreted carefully. In this study, patient 
numbers were small and data on physical activity 
was not collected. Daly et  al. studied a group of chil-
dren taking CGMP-AA vs L-AA over 12 months. They 
found no differences between CGMP-AA and L-AA for 
anthropometry at each of the measured time points but 
within the CGMP-AA group, weight and BMI z-scores 
increased significantly between baseline to 12  months 
[5].
The results from our study are very encouraging about 
the use of CGMP-AA in adult patients with PKU. It is 
well established that dietary non-adherence increases 
with age, commonly reflecting poor tolerance of the pro-
tein substitute [6]. The restrictive nature of the PKU diet 
as well as inadequate adherence with the fortified protein 
substitute is likely to cause sub-optimal nutritional intake 
and increase the risk of clinical and biochemical nutri-
tional deficiencies [36]. In this study, CGMP-AA enabled 
Table 4 Blood pressure and biochemical data of patients at baseline compared with last assessment
ApoA1, apolipoprotein A1; ApoB, apolipoprotein B; BUN, blood urea nitrogen; CGMP-AA, casein glycomacropeptide supplements; C, cholesterol; CRP, c-reactive 
protein; HbA1c, glycated haemoglobin; HDL-C, high-density lipoprotein-cholesterol; HOMA-IR, homeostatic model of insulin resistance; L-AA, phenylalanine-free 
L-amino acid supplements; LDL-C, low-density lipoprotein-cholesterol; Phe, phenylalanine; PKU, phenylketonuria; Tyr, tyrosine;  TL-AA, nutritional status evaluation 
under L-AA;  TCGMP-AA, last annual nutritional status evaluation under CGMP-AA; Vit, vitamin; VLDL-C, very low-density lipoprotein-cholesterol. Data are presented as 
mean ± S.D. (n) or median (P25–P75) (n). Paired t-test and Wilcoxon test were performed to identify differences when normal distribution or non-normal was found, 
respectively. Significance was set at the level of p value less than 0.05
Profile n TL-AA TCGMP-AA p value
Systolic blood pressure (mmHg) 11 112 ± 13 112 ± 11 1.000
Diastolic blood pressure (mmHg) 11 60 ± 15 63 ± 12 0.581
Heart rate (bpm) 11 73 ± 9 72 ± 8 0.607
Uric acid (mg/dL) 11 4.0 ± 0.8 4.0 ± 1.2 0.847
Glucose (mg/dL) 11 78.2 ± 6.8 75.6 ± 5.3 0.190
Creatinine (mg/dL) 11 0.7 ± 0.1 0.7 ± 0.1 0.676
Urea (mg/dL) 11 20.5 ± 7.6 23.2 ± 6.7 0.262
BUN (mg/dL) 11 1.68 ± 0.63 1.90 ± 0.55 0.268
HbA1c (%) 10 5.1 ± 0.4 5.0 ± 0.3 0.107
Total cholesterol (mg/dL) 11 165 ± 37 156 ± 34 0.349
HDL-C (mg/dL) 11 55 ± 14 51 ± 11 0.194
LDL-C (mg/dL) 11 93 ± 32 85 ± 32 0.265
VLDL-C (mg/dL) 11 17 ± 6 20 ± 10 0.121
Triglycerides (mg/dL) 11 84 ± 27 99 ± 50 0.140
ApoA1 (mg/dL) 10 153 ± 25 145 ± 31 0.187
ApoB (mg/dL) 10 82 ± 22 80 ± 22 0.612
Iron (μg/dL) 11 115 (85–135) 88 (48–144) 0.266
Transferrin (mg/dL) 11 271 ± 43 263 ± 44 0.554
Ferritin (ng/dL) 11 65 ± 35 52 ± 26 0.132
Albumin (g/dL) 11 4.69 ± 0.33 4.57 ± 0.17 0.112
Homocysteine (μmol/L) 8 8.44 ± 1.51 8.21 ± 1.32 0.820
Prealbumin (mg/dL) 11 240 (224–278) 272 (200–293) 0.575
CRP (mg/dL) 10 0.89 (0.72–2.46) 1.28 (0.77–2.92) 0.799
Insulin (μU/mL) 8 7.8 (7.3–13.6) 9.8 (6.5–18.3) 0.161
HOMA-IR 8 1.5 (1.4–2.5) 1.8 (1.2–3.5) 0.327
Calcium (mmol/L) 11 2.37 ± 0.12 2.33 ± 0.11 0.164
Phosphorus (mmol/L) 11 1.07 ± 0.24 0.98 ± 0.14 0.221
Selenium (μmol/L) 6 0.70 ± 0.30 0.96 ± 0.31 0.257
Zinc (μmol/L) 11 12.5 (9.7–17.4) 11.3 (10.4–12.4) 0.155
Vit. B12 (pg/L) 11 484 (413–734) 459 (301–1043) 0.722
Vit. D (nmol/L) 11 77 ± 26 70 ± 27 0.153
Folic acid (ng/mL) 9 12.9 ± 3.8 12.9 ± 5.3 0.996
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many adult patients to successfully remain on dietary 
treatment. Only 1 of 5 patients stopped taking CGMP-
AA due to poor adherence.
Our findings do have several limitations. Although we 
collected data over 6 years, the sample size is still small 
and only 55% (6 out 11 patients) of the patient cohort 
had > 2  years follow-up whilst taking CGMP-AA. Also, 
not all the patients replaced their full prescription of 
L-AA intake with CGMP-AA. In addition, the severity 
of disorder varied widely, with 5 patients having a milder 
phenotype, with increased Phe tolerance [23], minimis-
ing the impact of CGMP-AA on blood Phe levels. Also, 
patients’ blood Phe control at the start of the study was 
not optimal. This study had a retrospective design and 
dietary adherence is known to decrease with increasing 
age. We had no specific marker of adherence with L-AA 
or CGMP-AA, although we examined many biochemical 
and nutritional parameters. Dietary intake was collected 
Fig. 2 Median blood Phe levels of 11 patients with PKU taking L-AA versus CGMP-AA (last ANSE) with different percentages of contribution 
to the total protein substitute. CGMP-AA, casein glycomacropeptide supplements; L-AA, phenylalanine-free L-amino acid supplements; Phe, 
phenylalanine. Dashed line: target level of 480 µmol/L > 12 years. The number below each pair of bars represents Patient ID
Fig. 3 Median blood Tyr levels of 11 patients with PKU taking L-AA versus CGMP-AA (last ANSE) with different percentages of contribution to the 
total protein substitute. CGMP-AA, casein glycomacropeptide supplements; L-AA, phenylalanine-free L-amino acid supplements; Tyr, tyrosine. The 
number below each pair of bars represents Patient ID
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by a 24-h food recall method, and like other dietary 
assessment methods it is associated with disadvantages.
Conclusions
With this long-term work we can clearly state that the 
metabolic control and the biochemical nutritional status 
of patients with PKU did not deteriorate with time, but 
only 6 patients remained on CGMP-AA > 2  years dura-
tion. In addition, parameters of body composition and 
the percentage of overweight and obesity did not sig-
nificantly increase while taking CGMP-AA for a longer 
follow-up period.
This work suggests that CGMP-AA is safe and does not 
affect nutritional status even though it would be useful to 
have more studies replicating these results with a higher 
sample of patients. So far, the only difference observed 
to traditional L-AA is improved palatability which may 
contribute to better long-term adherence with protein 
substitute.
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